PMID- 36266430
OWN - NLM
STAT- MEDLINE
DCOM- 20221025
LR  - 20230112
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 12
IP  - 1
DP  - 2022 Oct 20
TI  - Comparison of the inhibitory effect of tocilizumab and etanercept on the 
      progression of joint erosion in rheumatoid arthritis treatment.
PG  - 17524
LID - 10.1038/s41598-022-22152-w [doi]
LID - 17524
AB  - We compared the efficacy of tocilizumab and etanercept in inhibiting radiographic 
      progression of joint destruction in rheumatoid arthritis. Overall, 187 patients 
      treated with etanercept or tocilizumab were selected. To adjust for baseline 
      patient characteristics between the tocilizumab and etanercept treatment groups, 
      a propensity score matching was performed. Radiographic progression of joint 
      destruction was compared between patients treated with tocilizumab or etanercept. 
      Clinical disease activity index (CDAI) and modified health assessment 
      questionnaire (mHAQ) scores at the administration of biologic treatment and after 
      12 months of tocilizumab and etanercept therapy were measured and compared to 
      radiographical parameters between the groups. Levels of C-reactive protein (CRP), 
      matrix metalloproteinase-3 (MMP-3), CDAI, and mHAQ scores improved after 
      12 months of treatment in the two groups. Proportion of patients with no Sharp 
      erosion score progression was significantly higher with tocilizumab treatment 
      than with etanercept treatment (p = 0.032). Multivariate analysis demonstrated 
      that Sharp erosion score was significantly associated with baseline CDAI (odds 
      ratio, 1.05; 95% confidence interval, 1.003-1.099, p = 0.037). Tocilizumab 
      treatment suppressed joint erosion progression compared to etanercept, and the 
      progression correlated with baseline CDAI.
CI  - (c) 2022. The Author(s).
FAU - Hayashi, Shinya
AU  - Hayashi S
AD  - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 
      7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. shayashi@med.kobe-u.ac.jp.
FAU - Matsubara, Tsukasa
AU  - Matsubara T
AD  - Department of Orthopaedic Surgery, Matsubara Mayflower Hospital, Kato, Japan.
FAU - Maeda, Toshihisa
AU  - Maeda T
AD  - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 
      7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
FAU - Fukuda, Koji
AU  - Fukuda K
AD  - Department of Orthopaedic Surgery, Matsubara Mayflower Hospital, Kato, Japan.
FAU - Funahashi, Keiko
AU  - Funahashi K
AD  - Department of Orthopaedic Surgery, Matsubara Mayflower Hospital, Kato, Japan.
FAU - Hashimoto, Marowa
AU  - Hashimoto M
AD  - Research Institute of Joint Diseases, Kobe, Japan.
FAU - Tsumiyama, Ken
AU  - Tsumiyama K
AD  - Department of Orthopaedic Surgery, Matsubara Mayflower Hospital, Kato, Japan.
FAU - Kamenaga, Tomoyuki
AU  - Kamenaga T
AD  - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 
      7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
FAU - Takashima, Yoshinori
AU  - Takashima Y
AD  - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 
      7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
FAU - Matsumoto, Tomoyuki
AU  - Matsumoto T
AD  - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 
      7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
FAU - Tachibana, Shotaro
AU  - Tachibana S
AD  - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 
      7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
FAU - Kuroda, Ryosuke
AU  - Kuroda R
AD  - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 
      7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
LA  - eng
PT  - Journal Article
DEP - 20221020
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biological Products)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - OP401G7OJC (Etanercept)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - I031V2H011 (tocilizumab)
RN  - 0 (Antibodies, Monoclonal, Humanized)
SB  - IM
MH  - Humans
MH  - *Antirheumatic Agents/therapeutic use
MH  - *Arthritis, Rheumatoid/drug therapy
MH  - *Biological Products/therapeutic use
MH  - C-Reactive Protein
MH  - Etanercept/therapeutic use
MH  - Matrix Metalloproteinase 3
MH  - Treatment Outcome
MH  - *Antibodies, Monoclonal, Humanized/therapeutic use
PMC - PMC9585052
COIS- The authors declare no competing interests.
EDAT- 2022/10/21 06:00
MHDA- 2022/10/25 06:00
PMCR- 2022/10/20
CRDT- 2022/10/20 23:39
PHST- 2022/06/12 00:00 [received]
PHST- 2022/10/10 00:00 [accepted]
PHST- 2022/10/20 23:39 [entrez]
PHST- 2022/10/21 06:00 [pubmed]
PHST- 2022/10/25 06:00 [medline]
PHST- 2022/10/20 00:00 [pmc-release]
AID - 10.1038/s41598-022-22152-w [pii]
AID - 22152 [pii]
AID - 10.1038/s41598-022-22152-w [doi]
PST - epublish
SO  - Sci Rep. 2022 Oct 20;12(1):17524. doi: 10.1038/s41598-022-22152-w.